Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.eprac.2020.12.015 http://scihub22266oqcxt.onion/10.1016/j.eprac.2020.12.015 33551315!7796656!33551315     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33551315&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Endocr+Pract 2021 ; 27 (2): 95-100 Nephropedia Template TP {{tp|p=33551315|t=2021. Hyperglycemia is Associated With Increased Mortality in Critically Ill Patients With COVID-19 |pdf=|usr=}}{{33551315}} gab.com Text Hyperglycemia is Associated With Increased Mortality in Critically Ill Patients With COVID-19 JO: Endocr Pract http://www.kidney.de/pget.php?&tw=1&pmid=33551315 #FOAvip OBJECTIVE: To explore the relationship between hyperglycemia in the presence and absence of diabetes mellitus (DM) and adverse outcomes in critically ill patients with coronavirus disease 2019 (COVID-19). METHODS: The study included 133 patients with COVID-19 admitted to an intensive care unit (ICU) at an urban academic quaternary-care center between March 10 and April 8, 2020. Patients were categorized based on the presence or absence of DM and early-onset hyperglycemia (EHG), defined as a blood glucose >180 mg/dL during the first 2 days after ICU admission. The primary outcome was 14-day all-cause in-hospital mortality; also examined were 60-day all-cause in-hospital mortality and the levels of C-reactive protein, interleukin 6, procalcitonin, and lactate. RESULTS: Compared to non-DM patients without EHG, non-DM patients with EHG exhibited higher adjusted hazard ratios (HRs) for mortality at 14 days (HR 7.51, CI 1.70-33.24) and 60 days (HR 6.97, CI 1.86-26.13). Non-DM patients with EHG also featured higher levels of median C-reactive protein (306.3 mg/L, P = .036), procalcitonin (1.26 ng/mL, P = .028), and lactate (2.2 mmol/L, P = .023). CONCLUSION: Among critically ill COVID-19 patients, those without DM with EHG were at greatest risk of 14-day and 60-day in-hospital mortality. Our study was limited by its retrospective design and relatively small cohort. However, our results suggest the combination of elevated glucose and lactate may identify a specific cohort of individuals at high risk for mortality from COVID-19. Glucose testing and control are important in individuals with COVID-19, even those without preexisting diabetes. Twit Text FOAVip Hyperglycemia is Associated With Increased Mortality in Critically Ill Patients With COVID-19 ????Endocr Pract http://www.kidney.de/pget.php?&tw=1&pmid=33551315 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33551315 #FOAvip English Wikipedia <ref>{{Cite pmid|33551315}}</ref> Hyperglycemia is Associated With Increased Mortality in Critically Ill Patients With COVID-19 #MMPMID33551315 Mazori AY; Bass IR; Chan L; Mathews KS; Altman DR; Saha A; Soh H; Wen HH; Bose S; Leven E; Wang JG; Mosoyan G; Pattharanitima P; Greco G; Gallagher EJ Endocr Pract 2021[Feb]; 27 (2): 95-100 PMID33551315show ga OBJECTIVE: To explore the relationship between hyperglycemia in the presence and absence of diabetes mellitus (DM) and adverse outcomes in critically ill patients with coronavirus disease 2019 (COVID-19). METHODS: The study included 133 patients with COVID-19 admitted to an intensive care unit (ICU) at an urban academic quaternary-care center between March 10 and April 8, 2020. Patients were categorized based on the presence or absence of DM and early-onset hyperglycemia (EHG), defined as a blood glucose >180 mg/dL during the first 2 days after ICU admission. The primary outcome was 14-day all-cause in-hospital mortality; also examined were 60-day all-cause in-hospital mortality and the levels of C-reactive protein, interleukin 6, procalcitonin, and lactate. RESULTS: Compared to non-DM patients without EHG, non-DM patients with EHG exhibited higher adjusted hazard ratios (HRs) for mortality at 14 days (HR 7.51, CI 1.70-33.24) and 60 days (HR 6.97, CI 1.86-26.13). Non-DM patients with EHG also featured higher levels of median C-reactive protein (306.3 mg/L, P = .036), procalcitonin (1.26 ng/mL, P = .028), and lactate (2.2 mmol/L, P = .023). CONCLUSION: Among critically ill COVID-19 patients, those without DM with EHG were at greatest risk of 14-day and 60-day in-hospital mortality. Our study was limited by its retrospective design and relatively small cohort. However, our results suggest the combination of elevated glucose and lactate may identify a specific cohort of individuals at high risk for mortality from COVID-19. Glucose testing and control are important in individuals with COVID-19, even those without preexisting diabetes. |*COVID-19[MESH] |*Hyperglycemia/epidemiology[MESH] |Blood Glucose[MESH] |Critical Illness[MESH] |Hospital Mortality[MESH] |Humans[MESH] |Intensive Care Units[MESH] |Retrospective Studies[MESH]Hyperglycemia is Associated With Increased Mortality in Critically Ill(epmc).pdf DeepDyve Pubget Overpricing